Literature DB >> 25039001

The axis AGE-RAGE-soluble RAGE and oxidative stress in chronic kidney disease.

Alejandro Gugliucci1, Teresita Menini.   

Abstract

Chronic kidney disease (CKD) has been shown to be associated with high oxidative stress and cardiovascular disease. In this chapter our focus will be on the role of advanced glycation end products (AGE) and their receptor, RAGE in CKD progression and their role on cardiovascular complications. We provide a succinct, yet comprehensive summary of the current knowledge, the challenges and the future therapeutic avenues that are stemming out from novel recent findings. We first briefly review glycation and AGE formation and the role of the kidney in their metabolism. Next, we focus on the RAGE, its signaling and role in oxidative stress. We address the possible role of soluble RAGEs as decoys and the controversy regarding this issue. We then provide the latest information on the specific role of both AGE and RAGE in inflammation and perpetuation of kidney damage in diabetes and in CKD without diabetes, which is the main purpose of the review. Finally, we offer an update on new avenues to target the AGE-RAGE axis in CKD.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25039001     DOI: 10.1007/978-3-319-07320-0_14

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  14 in total

Review 1.  RAGE and glyoxalase in kidney disease.

Authors:  Reiko Inagi
Journal:  Glycoconj J       Date:  2016-06-06       Impact factor: 2.916

Review 2.  More than just an enzyme: Dipeptidyl peptidase-4 (DPP-4) and its association with diabetic kidney remodelling.

Authors:  Shreyasi Gupta; Utpal Sen
Journal:  Pharmacol Res       Date:  2019-08-08       Impact factor: 7.658

Review 3.  Targeting Mitochondria and Reactive Oxygen Species-Driven Pathogenesis in Diabetic Nephropathy.

Authors:  Runa Lindblom; Gavin Higgins; Melinda Coughlan; Judy B de Haan
Journal:  Rev Diabet Stud       Date:  2015-08-10

4.  Effect of Advanced Glycation End-Products (AGE) Lowering Drug ALT-711 on Biochemical, Vascular, and Bone Parameters in a Rat Model of CKD-MBD.

Authors:  Neal X Chen; Shruthi Srinivasan; Kalisha O'Neill; Thomas L Nickolas; Joseph M Wallace; Matthew R Allen; Corinne E Metzger; Amy Creecy; Keith G Avin; Sharon M Moe
Journal:  J Bone Miner Res       Date:  2019-12-30       Impact factor: 6.390

5.  Inhibition of NA(+)/H(+) Exchanger 1 Attenuates Renal Dysfunction Induced by Advanced Glycation End Products in Rats.

Authors:  Peng Li; Geng-Rong Chen; Fu Wang; Ping Xu; Li-Ying Liu; Ya-Ling Yin; Shuang-Xi Wang
Journal:  J Diabetes Res       Date:  2015-11-30       Impact factor: 4.011

6.  Effect of Vitamin D Receptor Activation on the AGE/RAGE System and Myeloperoxidase in Chronic Kidney Disease Patients.

Authors:  Claudia Torino; Patrizia Pizzini; Sebastiano Cutrupi; Rocco Tripepi; Antonio Vilasi; Giovanni Tripepi; Francesca Mallamaci; Carmine Zoccali
Journal:  Oxid Med Cell Longev       Date:  2017-12-06       Impact factor: 6.543

Review 7.  Food Processing: The Influence of the Maillard Reaction on Immunogenicity and Allergenicity of Food Proteins.

Authors:  Malgorzata Teodorowicz; Joost van Neerven; Huub Savelkoul
Journal:  Nutrients       Date:  2017-08-04       Impact factor: 5.717

8.  The ratio of AGE to sRAGE independently associated with albuminuria in hypertensive patients.

Authors:  Kuang-Hsing Chiang; Jaw-Wen Chen; Shao-Sung Huang; Hsin-Bang Leu; Shing-Jong Lin; Po-Hsun Huang
Journal:  BMC Endocr Disord       Date:  2018-11-13       Impact factor: 2.763

9.  D-ribose induces nephropathy through RAGE-dependent NF-κB inflammation.

Authors:  Jinni Hong; Xuemei Wang; Ning Zhang; Hong Fu; Weiwei Li
Journal:  Arch Pharm Res       Date:  2018-08-13       Impact factor: 4.946

Review 10.  Role of advanced glycation end products in mobility and considerations in possible dietary and nutritional intervention strategies.

Authors:  Jie-Hua Chen; Xu Lin; Cuihong Bu; Xuguang Zhang
Journal:  Nutr Metab (Lond)       Date:  2018-10-10       Impact factor: 4.169

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.